Hemodiafiltration in Infants With Complications During Peritoneal Dialysis

• Published in: Artificial organs Vol. 36; no. 7; pp. 590 - 593
• Main Authors: Rödl, Siegfried, Marschitz, Ingrid, Mache, Christoph J., Nagel, Bert, Koestenberger, Martin, Zobel, Gerfried
• Format: Journal Article
• Language: English
• Published: Malden, USA Blackwell Publishing Inc 01.07.2012
• Subjects: Abdomen; Hemodiafiltration - adverse effects; Hemodiafiltration - methods; Humans; Infant; Infant, Newborn; Intermittent hemodiafiltration; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - therapy; Kidney Transplantation; Male; Peritoneal dialysis; Peritoneal Dialysis - adverse effects; Peritoneal Dialysis - methods; Peritonitis - complications; Peritonitis - therapy; Renal replacement therapy; Treatment Outcome
• ISSN: 0160-564X; 1525-1594
• DOI: 10.1111/j.1525-1594.2011.01434.x

End‐stage renal disease (ESRD) in neonates still has a high mortality, particularly in the first year of life. We present the combination of peritoneal dialysis (PD) with intermittent hemodiafiltration (iHDF) in neonates with ESRD. Four infants younger than 28 days were treated with PD and iHDF. Renal diagnoses leading to ESRD were cortical necrosis, prune belly syndrome, neonatal hemolytic uremic syndrome, and autosomal recessive polycystic kidney disease. Initially, three patients were on iHDF until PD was started. At the time when complications occurred during PD, patients were switched back to iHDF. iHDF was used five times as a bridge to PD in case of abdominal surgery. Two of the four patients were switched to iHDF because of peritoneal ultrafiltration failure due to recurrent peritoneal leaks. Once, iHDF became necessary due to refractory peritonitis. All four patients survived the first year of life. Two patients were transplanted successfully at an age of 35 and 22 months, respectively. The others are on renal replacement therapy, one on PD at the age of 28 months and one on iHDF at the age of 25 months, respectively. In case of PD complications, iHDF may be an appropriate bridge to achieve long‐term survival until kidney transplantation.